Evidence map›Paper›PMID 31175806›Full record

Trial reportThe American journal of clinical nutrition2019

Colonic mucosal and exfoliome transcriptomic profiling and fecal microbiome response to a flaxseed lignan extract intervention in humans.

Johanna W Lampe, Eunji Kim, Lisa Levy, Laurie A Davidson, Jennifer S Goldsby, Fayth L Miles, Sandi L Navarro, Timothy W Randolph, Ni Zhao, Ivan Ivanov and 5 more

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The American journal of clinical nutrition, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01619020 (Gut Microbiota and Colonic Gene Expression), which is not on this map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01619020 nacompletednot on this map

Gut Microbiota and Colonic Gene Expression: A Lignan Trial in Humans

TypeinterventionalSponsorFred Hutchinson Cancer CenterRan2012 to 2017Enrolled66ConditionsHealthyArmsFlaxseed Lignans
3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 57 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Johanna W LampePublic Health Sciences Division.
Eunji KimDepartment of Electrical & Computer Engineering.
Lisa LevyPublic Health Sciences Division.
Laurie A DavidsonCenter for Translational Environmental Health Research.
Jennifer S GoldsbyCenter for Translational Environmental Health Research.
Fayth L MilesPublic Health Sciences Division.
Sandi L NavarroPublic Health Sciences Division.
Timothy W RandolphClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Ni ZhaoDepartment of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD.
Ivan IvanovCenter for Translational Environmental Health Research.
Andrew M KazClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Christopher DammanSchool of Medicine, University of Washington, Seattle, WA.
David M HockenberyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Meredith A J HullarPublic Health Sciences Division.
Robert S ChapkinCenter for Translational Environmental Health Research.
Faculty of Public Health · GBUniversity of Washington · USFred Hutch Cancer Center · USJohns Hopkins University · USTexas A&M University · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Pilot--Health Science ResearchP30ES009106 · NIEHS · TEXAS A&M UNIVERSITY SYSTEM · PI SAFE, STEPHEN H. · 1998 to 2006
$9.2M
Plasma membrane therapy: Disruption of Wnt associated receptor spatiotemporal organization by membrane targeted dietary bioactives (MTDB)R35CA197707 · NCI · TEXAS A&M AGRILIFE RESEARCH · PI CHAPKIN, ROBERT STEPHEN · 2016 to 2022
$6.3M
Gut Microbiota and colonic gene expression: A ligran trial in humansU01CA162077 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI CHAPKIN, ROBERT STEPHEN, HULLAR, MEREDITH · 2011 to 2015
$3.2M
FHCRC High-Performance Computing ClusterS10OD020069 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KOOPERBERG, CHARLES L · 2015 to 2015
$600k
NCI NIH HHS P30 CA015704NCI NIH HHS R35 CA197707NCI NIH HHS U01 CA162077NIEHS NIH HHS P30 ES009106NIH HHS S10 OD020069
6 · The paper itself

Abstract

backgroundMicrobial metabolism of lignans from high-fiber plant foods produces bioactive enterolignans, such as enterolactone (ENL) and enterodiol (END). Enterolignan exposure influences cellular pathways important to cancer risk and is associated with reduced colon tumorigenesis in animal models and lower colorectal cancer risk in humans.

objectivesThe aim of this study was to test the effects of a flaxseed lignan supplement (50 mg secoisolariciresinol diglucoside/d) compared with placebo on host gene expression in colon biopsies and exfoliated colonocyte RNA in feces and fecal microbial community composition, and to compare responses in relation to ENL excretion.

methodsWe conducted a 2-period randomized, crossover intervention in 42 healthy men and women (20-45 y). We used RNA-seq to measure differentially expressed (DE) genes in colonic mucosa and fecal exfoliated cells through the use of edgeR and functional analysis with Ingenuity Pathway Analysis. We used 16S ribosomal RNA gene (V1-V3) analysis to characterize the fecal microbiome, and measured END and ENL in 24-h urine samples by gas chromatography-mass spectrometry.

resultsWe detected 32 DE genes (false discovery rate <0.05) in the exfoliome, but none in the mucosal biopsies, in response to 60 d of lignan supplement compared with placebo. Statistically significant associations were detected between ENL excretion and fecal microbiome measured at baseline and at the end of the intervention periods. Further, we detected DE genes in colonic mucosa and exfoliome between low- and high-ENL excreters. Analysis of biopsy samples indicated that several anti-inflammatory upstream regulators, including transforming growth factor β and interleukin 10 receptor, were suppressed in low-ENL excreters. Complementary analyses in exfoliated cells also suggested that low-ENL excreters may be predisposed to proinflammatory cellular events due to upregulation of nuclear transcription factor κB and NOS2, and an inhibition of the peroxisome proliferator-activated receptor γ network.

conclusionsThese results suggest that ENL or other activities of the associated gut microbial consortia may modulate response to a dietary lignan intervention. This has important implications for dietary recommendations and chemoprevention strategies. This study was registered at clinicaltrials.gov as NCT01619020.

Indexed as

Gene Expression ProfilingAdultColonCross-Over StudiesDouble-Blind MethodFecesFemaleFlaxGastrointestinal MicrobiomeGene Expression RegulationHumansIntestinal MucosaLignansMalePlant ExtractsLignansPlant Extractscolonenterolactonefecal microbiomegene expressionhuman interventionlignansecoisolariciresinol

Identifiers

PMID31175806
PMCPMC6669062
OpenAlexW2948371372

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.